User login
Key clinical point: Atogepant showed clinically relevant benefits in patients with chronic migraine (CM), making it the first calcitonin gene-related peptide (CGRP)-targeted, efficacious, and safe oral preventive treatment option for CM.
Major finding: Compared with placebo, the reduction in mean monthly migraine days at week 12 was significantly higher in patients who received 30 mg atogepant twice daily (adjusted least squares mean difference from placebo [LSMD] −2.4; P < .0001) and 60 mg once daily (adjusted LSMD −1.8; P = .0009). Constipation and nausea were the most common adverse events in both atogepant groups.
Study details: This phase 3 PROGRESS trial included 755 patients with CM who were randomly assigned to receive atogepant (30 mg twice daily or 60 mg once daily) or placebo.
Disclosures: This study was funded by Allergan (now AbbVie). Some authors declared receiving research support and personal and institutional fees from various sources, including AbbVie. Eleven authors declared being current or former employees or stockholders of AbbVie.
Source: Pozo-Rosich P et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 (Jul 26). doi: 10.1016/S0140-6736(23)01049-8
Key clinical point: Atogepant showed clinically relevant benefits in patients with chronic migraine (CM), making it the first calcitonin gene-related peptide (CGRP)-targeted, efficacious, and safe oral preventive treatment option for CM.
Major finding: Compared with placebo, the reduction in mean monthly migraine days at week 12 was significantly higher in patients who received 30 mg atogepant twice daily (adjusted least squares mean difference from placebo [LSMD] −2.4; P < .0001) and 60 mg once daily (adjusted LSMD −1.8; P = .0009). Constipation and nausea were the most common adverse events in both atogepant groups.
Study details: This phase 3 PROGRESS trial included 755 patients with CM who were randomly assigned to receive atogepant (30 mg twice daily or 60 mg once daily) or placebo.
Disclosures: This study was funded by Allergan (now AbbVie). Some authors declared receiving research support and personal and institutional fees from various sources, including AbbVie. Eleven authors declared being current or former employees or stockholders of AbbVie.
Source: Pozo-Rosich P et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 (Jul 26). doi: 10.1016/S0140-6736(23)01049-8
Key clinical point: Atogepant showed clinically relevant benefits in patients with chronic migraine (CM), making it the first calcitonin gene-related peptide (CGRP)-targeted, efficacious, and safe oral preventive treatment option for CM.
Major finding: Compared with placebo, the reduction in mean monthly migraine days at week 12 was significantly higher in patients who received 30 mg atogepant twice daily (adjusted least squares mean difference from placebo [LSMD] −2.4; P < .0001) and 60 mg once daily (adjusted LSMD −1.8; P = .0009). Constipation and nausea were the most common adverse events in both atogepant groups.
Study details: This phase 3 PROGRESS trial included 755 patients with CM who were randomly assigned to receive atogepant (30 mg twice daily or 60 mg once daily) or placebo.
Disclosures: This study was funded by Allergan (now AbbVie). Some authors declared receiving research support and personal and institutional fees from various sources, including AbbVie. Eleven authors declared being current or former employees or stockholders of AbbVie.
Source: Pozo-Rosich P et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 (Jul 26). doi: 10.1016/S0140-6736(23)01049-8